Bioventus announced today that it has started selling Osteomatrix+ – a moldable bone graft substitute intended for a variety of orthopedic and spine bone remodeling applications.
Bioventus officials boast that Osteomatrix+ has improved moldability, flexibility and versatility versus its predecessor.
“Osteomatrix+ represents the first of several next-generation products that will be added to the Bioventus portfolio in the next five years,” Bioventus CEO Tony Bihl said in a news release. “We will provide more diverse orthobiologic offerings for hospitals and efficacious solutions for both surgeons and their patients, as we continue to grow and serve these markets.
Osteomatrix+ is made of bovine collagen and biphasic, hydroxyapatite/ß-tricalcium phosphate granules. The mixture is meant to produce a reliable, porous scaffold, as well as sustained osteoconductivity throughout the bone remodeling process.
The bone graft is indicated for use in bony voids or gaps of the skeletal system not intrinsic to the stability of the bony structure. Such osseous defects can occur during surgery or after a traumatic bone injury. A health provider would combine Osteomatric+ with autologous bone marrow aspirate and pack it into the osseous defects.
Bioventus (Durham, N.C.) offers orthobiologics products for osteoarthritis, surgical and non-surgical bone healing.
